Jessica R Salas1,2, Bao Ying Chen1,2, Alicia Wong1,2, Sergio Duarte3, Stephanie A K Angarita3, Gerald S Lipshutz1,4,5, Owen N Witte1,4,6, Peter M Clark7,2,4. 1. Department of Molecular and Medical Pharmacology, University of California, Los Angeles California. 2. Crump Institute for Molecular Imaging, University of California, Los Angeles California. 3. Department of Surgery, University of California, Los Angeles California. 4. Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles California. 5. Intellectual and Developmental Disabilities Research Center, University of California, Los Angeles California; and. 6. Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles California. 7. Department of Molecular and Medical Pharmacology, University of California, Los Angeles California pclark@mednet.ucla.edu.
Abstract
Drug-induced liver failure is a significant indication for a liver transplant, and unexpected liver toxicity is a major reason that otherwise effective therapies are removed from the market. Various methods exist for monitoring liver injury but are often inadequate to predict liver failure. New diagnostic tools are needed. Methods: We evaluate in a preclinical model whether 18F-2-deoxy-2-fluoroarabinose (18F-DFA), a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure. Mice treated with vehicle, 100, 300, or 500 mg/kg acetaminophen for 7 or 21 h were imaged with 18F-FDG and 18F-DFA PET. Hepatic radiotracer accumulation was correlated to survival and percentage of nonnecrotic tissue in the liver. Mice treated with acetaminophen and vehicle or N-acetylcysteine were imaged with 18F-DFA PET. 18F-DFA accumulation was evaluated in human hepatocytes engrafted into the mouse liver. Results: We show that hepatic 18F-DFA accumulation is 49%-52% lower in mice treated with high-dose acetaminophen than in mice treated with low-dose acetaminophen or vehicle. Under these same conditions, hepatic 18F-FDG accumulation was unaffected. At 21 h after acetaminophen treatment, hepatic 18F-DFA accumulation can distinguish mice that will succumb to the liver injury from those that will survive it (6.2 vs. 9.7 signal to background, respectively). Hepatic 18F-DFA accumulation in this model provides a tomographic representation of hepatocyte density in the liver, with a R2 between hepatic 18F-DFA accumulation and percentage of nonnecrotic tissue of 0.70. PET imaging with 18F-DFA can be used to distinguish effective from ineffective resolution of acetaminophen-induced liver injury with N-acetylcysteine (15.6 vs. 6.2 signal to background, respectively). Human hepatocytes, in culture or engrafted into a mouse liver, have levels of ribose salvage activity similar to those of mouse hepatocytes. Conclusion: Our findings suggest that PET imaging with 18F-DFA can be used to visualize and quantify drug-induced acute liver injury and may provide information on the progression from liver injury to hepatic failure.
Drug-induced liver failure is a significant indication for a liver transplant, and unexpected liver toxicity is a major reason that otherwise effective therapies are removed from the market. Various methods exist for monitoring liver injury but are often inadequate to predict liver failure. New diagnostic tools are needed. Methods: We evaluate in a preclinical model whether 18F-2-deoxy-2-fluoroarabinose (18F-DFA), a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure. Mice treated with vehicle, 100, 300, or 500 mg/kg acetaminophen for 7 or 21 h were imaged with 18F-FDG and 18F-DFA PET. Hepatic radiotracer accumulation was correlated to survival and percentage of nonnecrotic tissue in the liver. Mice treated with acetaminophen and vehicle or N-acetylcysteine were imaged with 18F-DFA PET. 18F-DFA accumulation was evaluated in human hepatocytes engrafted into the mouse liver. Results: We show that hepatic 18F-DFA accumulation is 49%-52% lower in mice treated with high-dose acetaminophen than in mice treated with low-dose acetaminophen or vehicle. Under these same conditions, hepatic 18F-FDG accumulation was unaffected. At 21 h after acetaminophen treatment, hepatic 18F-DFA accumulation can distinguish mice that will succumb to the liver injury from those that will survive it (6.2 vs. 9.7 signal to background, respectively). Hepatic 18F-DFA accumulation in this model provides a tomographic representation of hepatocyte density in the liver, with a R2 between hepatic 18F-DFA accumulation and percentage of nonnecrotic tissue of 0.70. PET imaging with 18F-DFA can be used to distinguish effective from ineffective resolution of acetaminophen-induced liver injury with N-acetylcysteine (15.6 vs. 6.2 signal to background, respectively). Human hepatocytes, in culture or engrafted into a mouse liver, have levels of ribose salvage activity similar to those of mouse hepatocytes. Conclusion: Our findings suggest that PET imaging with 18F-DFA can be used to visualize and quantify drug-induced acute liver injury and may provide information on the progression from liver injury to hepatic failure.
Authors: Lennox J Jeffers; Rafael A Cortes; Pablo A Bejarano; Esther Oh; Arie Regev; Katie M Smith; Maria De Medina; Margaret Smith-Riggs; Marlene Colon; Keith Hettinger; Sandra Jara; Tulia Patricia Mendez; Eugene R Schiff Journal: Gastroenterol Hepatol (N Y) Date: 2007-05
Authors: K D Horn; P Wax; S M Schneider; T G Martin; J S Nine; M A Moraca; M A Virji; P A Aronica; K N Rao Journal: Am J Clin Pathol Date: 1999-09 Impact factor: 2.493
Authors: Peter M Clark; Victoria A Ebiana; Laura Gosa; Timothy F Cloughesy; David A Nathanson Journal: J Nucl Med Date: 2017-04-06 Impact factor: 10.057
Authors: Ashish Singhal; Saraschand Vadlamudi; Kenneth Stokes; Francis P Cassidy; Ayumi Corn; Stan S Shrago; Harlan I Wright; Vivek Kohli Journal: Transpl Int Date: 2012-04-05 Impact factor: 3.782
Authors: Robert S Brown; Mark W Russo; Michelle Lai; Mitchell L Shiffman; Michael C Richardson; James E Everhart; Jay H Hoofnagle Journal: N Engl J Med Date: 2003-02-27 Impact factor: 91.245
Authors: Patricia Iozzo; Fabian Geisler; Vesa Oikonen; Maija Mäki; Teemu Takala; Olof Solin; Ele Ferrannini; Juhani Knuuti; Pirjo Nuutila Journal: J Nucl Med Date: 2003-05 Impact factor: 10.057
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: Chengyi J Shu; Caius G Radu; Stephanie M Shelly; Dan D Vo; Robert Prins; Antoni Ribas; Michael E Phelps; Owen N Witte Journal: Int Immunol Date: 2008-12-23 Impact factor: 4.823
Authors: Jessica R Salas; Bao Ying Chen; Alicia Wong; Donghui Cheng; John S Van Arnam; Owen N Witte; Peter M Clark Journal: J Nucl Med Date: 2018-04-26 Impact factor: 10.057
Authors: Bao Ying Chen; Chiara Ghezzi; Brendon Villegas; Andrew Quon; Caius G Radu; Owen N Witte; Peter M Clark Journal: J Nucl Med Date: 2019-10-25 Impact factor: 10.057